Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT07678580 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Albumin-bound paclitaxel
RADIATION: Low-dose Short-course Radiotherapy
RADIATION: High-dose Short-course Radiotherapy
DRUG: Tislelizumab Combined With Chemotherapy for 3 cycles
DRUG: Carboplatin (AUC 5)

Sponsor

Tang-Du Hospital